Table 4 Incidence of premonitory symptoms that were followed by headache prior to galcanezumab treatment
| Â | Incidence % | Â | ||
|---|---|---|---|---|
Premonitory symptoms | All patients | Responders | Non responders | Fisher exact |
Neck stiffness | 54.3 | 59.3 | 47.4 | 0.550 |
Cognitive impairment | 54.3 | 63.0 | 42.1 | 0.231 |
Photophobia | 39.1 | 48.1 | 26.3 | 0.21 |
Irritability | 39.1 | 48.1 | 26.3 | 0.219 |
Fatigue | 37.0 | 44.4 | 26.3 | 0.235 |
Stress/nervous | 32.6 | 33.3 | 31.6 | 1.000 |
Vertigo/dizziness | 30.4 | 37.0 | 21.1 | 0.335 |
Nausea | 28.3 | 29.6 | 26.3 | 1.000 |
Phonophobia | 28.3 | 40.7 | 10.5 | 0.044 |
Osmophobia | 17.4 | 22.2 | 10.5 | 0.439 |
Ringing in the ear | 15.2 | 18.5 | 10.5 | 0.682 |
Yawning | 13.0 | 22.2 | 0.0 | 0.034 |